secwatch / observer
8-K filed May 22, 2024, 7:59 PM ET ticker XBIO CIK 0001534525
leadership confidence high sentiment neutral materiality 0.60

Xenetic Biosciences CEO Eisenberg and CSO Lockshin depart; CFO Parslow named interim CEO

Xenetic Biosciences, Inc.

item 5.02item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jeffrey F. Eisenberg

Director
XBIO · Xenetic Biosciences, Inc.
Effective
2024-05-16
Filed
May 22, 2024, 7:59 PM ET
and in connection therewith, Mr. Eisenberg resigned as a director of the Company and all of its subsidiaries, as applicable.
Departed

Dr. Curtis Lockshin

Chief Scientific Officer
XBIO · Xenetic Biosciences, Inc.
Effective
2024-05-16
Filed
May 22, 2024, 7:59 PM ET
In addition on May 16, 2024, the Company and Dr. Curtis Lockshin mutually agreed that Dr. Lockshin would step down as the Chief Scientific Officer of the Company, effective immediately.
Departed

Jeffrey F. Eisenberg

Chief Executive Officer
XBIO · Xenetic Biosciences, Inc.
Effective
2024-05-16
Successor
James F. Parslow
Filed
May 22, 2024, 7:59 PM ET
On May 16, 2024, the Company and Jeffrey F. Eisenberg mutually agreed that Mr. Eisenberg would step down as the Chief Executive Officer of the Company, effective immediately
Appointed (interim)

James F. Parslow

Interim Chief Executive Officer
XBIO · Xenetic Biosciences, Inc.
Effective
2024-05-16
Filed
May 22, 2024, 7:59 PM ET
On May 16, 2024, the Board of Directors (the “Board”) of Xenetic Biosciences, Inc. (the “Company”) appointed James F. Parslow, the Company’s Chief Financial Officer, to the position of Interim Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey F. Eisenberg resigned as Director at Xenetic Biosciences, Inc..

Action
resigned
Role
Director
Exact text from the filing
and in connection therewith, Mr. Eisenberg resigned as a director of the Company and all of its subsidiaries, as applicable.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Curtis Lockshin departed as Chief Scientific Officer at Xenetic Biosciences, Inc..

Action
stepped down
Role
Chief Scientific Officer
Exact text from the filing
In addition on May 16, 2024, the Company and Dr. Curtis Lockshin mutually agreed that Dr. Lockshin would step down as the Chief Scientific Officer of the Company, effective immediately.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey F. Eisenberg departed as Chief Executive Officer at Xenetic Biosciences, Inc..

Action
stepped down
Role
Chief Executive Officer
Exact text from the filing
On May 16, 2024, the Company and Jeffrey F. Eisenberg mutually agreed that Mr. Eisenberg would step down as the Chief Executive Officer of the Company, effective immediately
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

James F. Parslow was appointed as Interim Chief Executive Officer at Xenetic Biosciences, Inc..

Action
appointed
Role
Interim Chief Executive Officer
Exact text from the filing
On May 16, 2024, the Board of Directors (the “Board”) of Xenetic Biosciences, Inc. (the “Company”) appointed James F. Parslow, the Company’s Chief Financial Officer, to the position of Interim Chief Executive Officer.
View on SEC.gov

Xenetic Biosciences, Inc. filing history →

Source: SEC EDGAR
accession 0001683168-24-003779
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.